Table 4.
|
All-cause deaths |
Breast cancer-specific deaths |
||
---|---|---|---|---|
Model 1* HR (95% CI) |
Model 2** HR (95% CI) |
Model 1** HR (95% CI) |
Model 2** HR (95% CI) |
|
Overall |
0.96 (0.86-1.06) |
0.92 (0.83-1.02) |
0.99 (0.88-1.10) |
0.94 (0.84-1.05) |
Subtype† |
|
|
|
|
HR+/HER2- |
N/A |
0.92 (0.75-1.11) |
N/A |
0.92 (0.74-1.15) |
HR+/HER2+ |
0.87 (0.62-1.22) |
1.00 (0.69-1.46) |
||
HR-/HER2+ |
0.99 (0.74-1.31) |
1.08 (0.80-1.46) |
||
Triple negative |
0.93 (0.78-1.10) |
0.93 (0.77-1.12) |
||
Unclassified |
0.86 (0.66-1.13) |
0.88 (0.65-1.19) |
||
Race/ethnicity‡ |
|
|
|
|
NH White |
0.90 (0.76-1.06) |
0.89 (0.75-1.05) |
0.93 (0.78-1.12) |
0.92 (0.77-1.11) |
NH Black |
0.93 (0.71-1.21) |
0.89 (0.68-1.16) |
0.97 (0.72-1.29) |
0.91 (0.68-1.22) |
Hispanic |
1.01 (0.85-1.20) |
0.95 (0.80-1.14) |
1.05 (0.87-1.27) |
0.99 (0.82-1.20) |
NH Asian/Pacific Islander |
1.01 (0.75-1.35) |
0.98 (0.73-1.31) |
1.02 (0.73-1.41) |
0.98 (0.71-1.37) |
Unknown |
N/A |
N/A |
N/A |
N/A |
AJCC stage at diagnosis |
|
|
|
|
I |
0.97 (0.65-1.43) |
0.95 (0.64-1.40) |
1.44 (0.90-2.31) |
1.38 (0.86-2.21) |
II |
0.95 (0.79-1.15) |
0.90 (0.74-1.08) |
0.98 (0.79-1.21) |
0.91 (0.73-1.13) |
III |
1.02 (0.86-1.21) |
0.97 (0.82-1.15) |
1.06 (0.88-1.27) |
1.01 (0.84-1.21) |
IV |
0.86 (0.70-1.06) |
0.86 (0.70-1.05) |
0.86 (0.69-1.07) |
0.86 (0.69-1.07) |
Unknown | 1.10 (0.70-1.74) | 1.09 (0.69-1.72) | 1.02 (0.59-1.77) | 1.03 (0.59-1.78) |
* Reference group for each model was women 40 to 64 years of age at diagnosis. Cox models were adjusted for all variables in the table and year of diagnosis (continuous), marital status at diagnosis, tumor grade, neighborhood SES (quintile), and first course of treatment (chemotherapy (y/n), radiation (y/n), and surgery (y/n)). AJCC stage levels I through IV and unknown were included as a stratifying variable.
** Cox models were additionally adjusted for subtypes of breast cancer.
† Human epidermal growth factor receptor 2 (HER2), hormone receptor (HR), triple-negative (estrogen-receptor negative, progesterone-receptor negative, HER2-negative).
‡ Non-Hispanic.